Sarepta Therapeutics | SRPT - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
BioCryst Pharmaceuticals USD 63.98M 31.8M 2026-06
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Capricor Therapeutics USD 1.92M 446.47K 2025-12
Daiichi Sankyo JPY 237.75B 12.21B 2026-09
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Incyte USD 364.27M 12.54M 2026-09
Insmed USD 253.03M 5.56M 2026-09
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
Moderna USD 282M 66M 2026-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.31B 325M 2026-09
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Tectonic Therapeutic USD 6.17M 260K 2026-06
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09